Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities (2012 - 2026)

Enanta Pharmaceuticals' Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $197.8 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 13.69% year-over-year to $197.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $197.8 million (down 13.69% YoY) and the FY2025 annual result came in at $215.8 million, down 12.86% from the prior year.
• Total Non-Current Liabilities was $197.8 million for Q1 2026 at Enanta Pharmaceuticals, up from $100.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $249.7 million in Q2 2024 and bottomed at $46.3 million in Q4 2022.
• A 5-year average of $137.9 million and a median of $100.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 409.83% — and 2025, when it tumbled 59.22%.
• Enanta Pharmaceuticals' Total Non-Current Liabilities stood at $46.3 million in 2022, then soared by 409.83% to $236.0 million in 2023, then gained by 0.26% to $236.6 million in 2024, then sank by 57.69% to $100.1 million in 2025, then surged by 97.66% to $197.8 million in 2026.
• Business Quant data shows ENTA's Total Non-Current Liabilities at $197.8 million in Q1 2026, $100.1 million in Q4 2025, and $215.8 million in Q3 2025.